Sartorius Group
Annual Report
2020
“The pandemic year of 2020 was exceptional and very challenging for Sartorius as well. In a very intense and demanding environment, we experienced the strongest year of growth in the company's recent history and were simultaneously able to complete several strategically important acquisitions. Our strategy and business model proved not only to be particularly resilient in the face of the pandemic. Sartorius has also been contributing directly toward overcoming this pandemic: each and every day, we deliver essential products and technologies to vaccine manufacturers all over the world for producing coronavirus vaccines.”
Sales revenue
€2,335.7m
in constant FX: 30.2%
Underlying EBITDA
€692.2m
+39.6%
Order intake
€2,836.3m
in constant FX: 49.0%
Employees
10,637
+1,601
Market capitalization
~€23.6bn
+88.3%
Group Business Development and Divisions
Sartorius recorded high growth in 2020 due to strong organic development, several acquisitions and the additional momentum from business related to the coronavirus pandemic. The Group closed the year with significant double-digit growth rates in sales revenue, order intake and earnings, reporting further gains in both divisions and across all geographies.
Bioprocess Solutions
In the Bioprocess Solutions Division, Sartorius offers a broad product portfolio that covers all steps in the production of a biopharmaceutical. The company has held leading market positions for years in its core technologies, such as filtration, fermentation, cell cultivation and fluid management.
Lab Products & Services
The Lab Products & Services Division offers laboratories in the pharmaceutical and biopharmaceutical industries as well as at academic research institutes innovative solutions for bioanalytics, in addition to premium laboratory products, consumables and services. Sartorius is among the market leaders in laboratory balances, pipettes and lab consumables.